-
Uncategorized2 months ago
Soleno sold at a discount to Neurocrine due to dwindling European prospects
Soleno sold at a discount to Neurocrine due to dwindling European prospects
-
Uncategorized2 months ago
Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine
The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger RNA to gene therapy. Read More
-
Uncategorized2 months agoOpinion: What happens when a chief executive loses executive functions?
Circa 1970, the renowned Russian neuropsychologist Alexander Luria together with Karl Pribram from Stanford University and other neuroscientists of that era introduced the term “executive functions” into the scientific lexicon to denote...
-
Uncategorized2 months ago
As Duchenne innovation booms, let’s ensure it becomes real progress
At Sarepta Therapeutics, we’ve seen it all. Here are the questions I believe we should be asking to move forward in Duchenne muscular dystrophy.
-
Uncategorized2 months ago
CleanAssure Launched as an ISO Class 5 Controlled Cleanroom for Sterile Single-Use Assemblies
Freudenberg Medical, a Kaiserslautern, Germany-based contract design manufacturing partner, launched CleanAssure, a new ISO Class 5 controlled cleanroom designed to deliver clean and sterile single-use assemblies...
-
Uncategorized2 months ago
Replimmune ramps up layoffs to cover 60% of workforce amid ongoing fallout of FDA rejection
Replimune is saying goodbye to a further 161 staffers across two Massachusetts sites.Read More
-
Uncategorized2 months agoSTAT+: At AACR, a provocative use of CAR-T, Merck’s new thing and cancer’s geography problem
You’re reading the web version of STAT’s popup newsletter, AACR in 30 seconds, your guide to what’s happening at the American Association of Cancer Researchers’ annual...
-
Uncategorized2 months agoSTAT+: Former banker brought on to revitalize Pfizer’s strategy departs his post
Pfizer executive Andrew Baum, a former analyst at the investment bank Citi who joined the company in June 2024 to redirect its strategic approach, has left...
-
Uncategorized2 months agoSynthetic Biology and Tissue Engineering Grow Liver Tissue In‑Body
Damage to the liver in patients developing end-stage liver disease has become too severe for the organ’s normally extraordinary regenerative capacity to repair or compensate for...
-
Uncategorized2 months agoSTAT+: In early trial, CAR-T results raise hope of preventing multiple myeloma in high-risk patients
SAN DIEGO — Alison Cameron spent close to a decade fighting to keep myeloma under control. She’d been diagnosed with smoldering multiple myeloma, a precursor to...
STAT+: Up and down the ladder: The latest comings and goings
FDA imposes import alert on Indian plant after inspectors flag GMP failings
